Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with ESR1-mutated, ER-positive, HER2-negative ABC By Ogkologos - June 4, 2025 780 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Talazoparib Plus Enzalutamide Improves rPFS Over Placebo Plus Enzalutamide in First-Line... June 7, 2023 Vax-On Points to Maintenance of Active Anticancer Treatment Throughout the Whole... September 24, 2021 How Running and Training for a Marathon Helped Me Cope After... August 22, 2023 Teclistamab Shows Promise for People with Heavily Pretreated Multiple Myeloma September 29, 2022 Load more HOT NEWS Ovarian Function Suppression Plus Tamoxifen Significantly Reduces Premenopausal Breast Cancer Recurrence... EU Cancer Mission and Partners Launch First Cancer Mission Forum for... The Grace Project Helps Breast Cancer Survivors Practice Body Acceptance and... EMA Recommends Refusal of the Marketing Authorisation for Pexidartinib
